These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 30681655)

  • 21. Fremanezumab for the preventive treatment of migraine.
    Silberstein SD; Cohen JM; Yeung PP
    Expert Opin Biol Ther; 2019 Aug; 19(8):763-771. PubMed ID: 31177856
    [No Abstract]   [Full Text] [Related]  

  • 22. Antigens and Antibodies in Disease With Specifics About CGRP Immunology.
    Taylor FR
    Headache; 2018 Nov; 58 Suppl 3():230-237. PubMed ID: 30187471
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic antibodies against CGRP or its receptor.
    Bigal ME; Walter S; Rapoport AM
    Br J Clin Pharmacol; 2015 Jun; 79(6):886-95. PubMed ID: 25614243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Galcanezumab for the prevention of migraine.
    Frerichs LM; Friedman DI
    Pain Manag; 2021 Mar; 11(2):101-112. PubMed ID: 33291980
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis.
    Zhu Y; Liu Y; Zhao J; Han Q; Liu L; Shen X
    Neurol Sci; 2018 Dec; 39(12):2097-2106. PubMed ID: 30182284
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CGRP/CGRP Receptor Antibodies: Potential Adverse Effects Due to Blockade of Neovascularization?
    Majima M; Ito Y; Hosono K; Amano H
    Trends Pharmacol Sci; 2019 Jan; 40(1):11-21. PubMed ID: 30502971
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Calcitonin-gene-related peptide pathway mAbs and migraine prevention.
    Paemeleire K; MaassenVanDenBrink A
    Curr Opin Neurol; 2018 Jun; 31(3):274-280. PubMed ID: 29432219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population pharmacokinetic modelling and simulation of fremanezumab in healthy subjects and patients with migraine.
    Fiedler-Kelly JB; Cohen-Barak O; Morris DN; Ludwig E; Rasamoelisolo M; Shen H; Levi M
    Br J Clin Pharmacol; 2019 Dec; 85(12):2721-2733. PubMed ID: 31418911
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Biology of Monoclonal Antibodies: Focus on Calcitonin Gene-Related Peptide for Prophylactic Migraine Therapy.
    Raffaelli B; Reuter U
    Neurotherapeutics; 2018 Apr; 15(2):324-335. PubMed ID: 29616494
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of anti-calcitonin gene-related peptide monoclonal antibodies for treatment of chronic migraine: A systematic review and network meta-analysis.
    Soni P; Chawla E
    Clin Neurol Neurosurg; 2021 Oct; 209():106893. PubMed ID: 34464833
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CGRP as a new target in prevention and treatment of migraine.
    Diener HC
    Lancet Neurol; 2014 Nov; 13(11):1065-1067. PubMed ID: 25297015
    [No Abstract]   [Full Text] [Related]  

  • 32. Monthly versus quarterly fremanezumab for the prevention of migraine: a systemic review and meta-analysis from randomized controlled trials.
    Gao B; Lu Q; Wan R; Wang Z; Yang Y; Chen Z; Wang Z
    Naunyn Schmiedebergs Arch Pharmacol; 2021 Apr; 394(4):819-828. PubMed ID: 33136176
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Botulinum Toxin in the Treatment of Headache.
    Becker WJ
    Toxins (Basel); 2020 Dec; 12(12):. PubMed ID: 33348571
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: comparisons across randomized controlled studies.
    Mitsikostas DD; Reuter U
    Curr Opin Neurol; 2017 Jun; 30(3):272-280. PubMed ID: 28240610
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lasmiditan (Reyvow) and ubrogepant (Ubrelvy) for acute treatment of migraine.
    Med Lett Drugs Ther; 2020 Mar; 62(1593):35-39. PubMed ID: 32555120
    [No Abstract]   [Full Text] [Related]  

  • 36. A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody.
    Kielbasa W; Helton DL
    Cephalalgia; 2019 Sep; 39(10):1284-1297. PubMed ID: 30917684
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Raynaud's Phenomenon Associated With Calcitonin Gene-Related Peptide Monoclonal Antibody Antagonists.
    Evans RW
    Headache; 2019 Sep; 59(8):1360-1364. PubMed ID: 31310337
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Calcitonin Gene-Related Protein (CGRP)-Targeted Treatments for Migraine Prevention.
    Tepper DE
    Headache; 2019 Mar; 59(3):477-480. PubMed ID: 30825209
    [No Abstract]   [Full Text] [Related]  

  • 39. CGRP Antibodies as Prophylaxis in Migraine.
    Edvinsson L
    Cell; 2018 Dec; 175(7):1719. PubMed ID: 30550780
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Galcanezumab: First Global Approval.
    Lamb YN
    Drugs; 2018 Nov; 78(16):1769-1775. PubMed ID: 30378008
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.